IN8bio Reports 100% of AML Patients in Remission at EHA Congress
INB-100 Trial Success
IN8bio, Inc. has made a groundbreaking announcement at the 2024 European Hematology Association (EHA) Congress, reporting that 100% of Acute Myeloid Leukemia (AML) patients treated with their INB-100 therapy remain in complete remission (CR). This remarkable achievement is a significant milestone in the field of cancer treatment, showcasing the potential of gamma-delta T cell therapies for AML.
Expanding Enrollments and Future Trials
Following the success of the INB-100 trial, IN8bio is expanding enrollment to approximately 25 patients at the recommended Phase 2 dose. Additionally, the company has received FDA guidance for a future registrational trial for INB-100, paving the way for its potential approval as a groundbreaking therapy for AML.
Financial Stability and Growth
IN8bio closed a private placement for net proceeds of $11.6 million in October 2024, extending their cash runway through 2025. This financial stability allows the company to continue its innovative research and development efforts in the field of gamma-delta T cell therapies, bringing hope to patients with AML and other cancer types.
Impact on Patients
For patients diagnosed with AML, the success of the INB-100 trial is a beacon of hope. The prospect of achieving remission and potentially receiving a groundbreaking therapy like INB-100 offers new possibilities for improved outcomes and quality of life. IN8bio’s commitment to advancing cancer treatment through innovative therapies is a promising development for AML patients worldwide.
Global Impact
The success of the INB-100 trial and IN8bio’s innovative approach to cancer treatment have the potential to ripple across the world. As more patients benefit from groundbreaking therapies like INB-100, the landscape of cancer treatment could be transformed, offering new hope and possibilities for improved outcomes. IN8bio’s achievements mark a significant step forward in the fight against cancer, with far-reaching implications for the global healthcare community.
Conclusion
IN8bio’s success in the INB-100 trial represents a major milestone in the field of cancer treatment, particularly for patients with AML. The company’s innovative approach to gamma-delta T cell therapies offers new hope and possibilities for improved outcomes, both for individual patients and the global healthcare community. As we look towards the future, the impact of IN8bio’s achievements is poised to shape the landscape of cancer treatment, bringing us closer to a world where AML and other cancer types can be effectively treated and managed.
